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| Preparation of FVIII samples for activation studies
N8-GP and N8 had specific activities of 9974 and 8963 IU/mg FVIII protein, respectively, as determined by COAMATIC Factor VIII (Chromogenix, Milan, Italy), and were dissolved by adding 0.9% (w/v) NaCl. The FVIII solutions, possessing an activity level between 400 and 800 IU/mL, were aliquoted and frozen at −80°C. An aliquot was thawed before use and diluted to 30-100 IU/mL in 20 mmol/L Hepes, pH 7.4, containing 0.15 mol/L NaCl and 10 mg/mL bovine serum albumin. The sample was further diluted to 3-10 IU/mL in FVIII-deficient plasma and finally diluted to 0.3-1 IU/mL in Hepes buffer for assay use (except thrombin activation studies [direct dilution in Hepes buffer to 10 IU/mL]).
| Modified COATEST SP FVIII chromogenic assay
The COATEST solutions were prepared as instructed by the manufacturer (Chromogenix, Milan, Italy) in the package insert. Fifty microliters (μL) of FVIII sample (N8 or N8-GP; 0.6 IU/mL) was then mixed with 50 μL FVIII-deficient plasma and 50 μL APTT reagent to resemble the APTT assay contact phase. Controls were included in which Hepes buffer replaced FVIII and/or plasma and/or APTT reagent. A sample of 25 μL was immediately withdrawn from these mixtures and added to 50 μL of the prepared COATEST solution containing FIXa, FX, phospholipid (and thrombin activity), followed by 5 minutes of incubation at 37°C. COATEST CaCl 2 solution (25 μL) was added followed by 3 minutes of incubation. FXa formation was terminated and quantified by adding 50 μL of the COATEST solution containing S-2765/I-2581 (and excess EDTA), after which the microtiter plate was
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• Clinical laboratory awareness of the importance of the choice of N8-GP assay reagent warranted. placed in a SpectraMax 340PC spectrophotometer and the absorbance increase at 405 nm monitored for 2 minutes.
| FXa generation assay mimicking one-stage FVIII clotting assay
Twenty-five microliters (μL) of FVIII sample (N8, N8-GP; 0.3-1 IU/mL) was mixed with 25 μL FVIII-deficient plasma (containing 10 mmol/L GPRP) and 25 μL APTT reagent, and incubated at 37°C for the time period recommended in the APTT reagent inserts for OS clotting assay. This step thus represents the APTT assay contact phase. Fifty microliters (μL) of 0.375 mmol/L S-2765 in 20 mmol/L Hepes buffer, pH 7.4, containing 0.15 mol/L NaCl and 8.75 mmol/L CaCl 2 , was added followed by continuous measurement of the increase in absorbance at 405 nm for 10 minutes. These two steps combined represent an entire APTT assay with its contact and clotting phases. The sum of any preexisting enzymatic activity in the plasma and activity generated during the contact phase was assessed in a sample where Hepes buffer replaced FVIII. In addition, a separate experiment was conducted where excess EDTA alone or EDTA solution containing 100 nmol/L hirudin was added at a time point when the absorbance in a mixture containing N8 had become significantly greater than in the buffer blank,
showing that the FVIII-dependent activity measured only stemmed from FXa without detectable contribution from thrombin.
| One-stage clotting assay
FVIII samples to be used in this assay were prepared by dilution to 10 IU/ mL in Hepes buffer containing 10 mg/mL bovine serum albumin, followed by dilution to 1 IU/mL in FVIII-deficient plasma before being placed in the instrument. Alternatively, normal human plasma (SSCLOT4) was used as the sample. The clotting assay was performed on an ACL TOP 550 instrument, using APTT reagents according to the manufacturer's instructions and adhering to the variable duration of the contact activation phase.
With APTT-SP and Pathromtin SL, contact activation phases of shorter and longer duration than recommended were also employed.
| FXIa activity measurements
Diluent (the one used in the ACL TOP instrument; 37°C), ice-cold SSCLOT4 plasma and APTT reagent (37°C) were mixed and incubated at 37°C, thus mimicking the contact activation phase of the OS clotting assay. Samples were withdrawn half way into the contact activation phase, at the end of it (duration as recommended by the manufacturer; see Table 1 ), as well as after twice the duration. Sample quenching and quantification of FXIa activity content according to a modified Rox Factor XIa method were performed as described, 11 except that the samples from FXIa generation in plasma were diluted only 100-fold in MES buffer. The FXIa concentrations in the samples were derived from a standard curve made from the purchased FXIa (using the specific activity provided on data sheet from Enzyme Research Laboratories).
TA B L E 1 Factor XIa accumulation in normal human plasma (SSCLOT4) during a contact activation phase of recommended duration (CAP-RD) and the ensuing recorded clotting time after recalcification (mean ± SD, n = 3) 
| FVIII activation by thrombin
Thrombin activation of N8 and N8-GP was studied by mixing 40 μL 
| Assessment of silica adsorption
Ten units of N8-GP or N8 in Hepes buffer was incubated with half the volume of APTT-SP or APTT-SP diluted to various degrees with APTT-SP supernatant. For this purpose, APTT-SP supernatant was collected after spinning APTT-SP for 10 minutes at 10 000 g. After 5 minutes of incubation at 37°C, the mixture was centrifuged for 10 minutes at 10 000 g. A sample of the supernatant (65 μL) was transferred to 35 μL reducing sample buffer, and 18 μL (~1.4 U of N8-GP/N8) was eventually applied on a polyacrylamide gel. SDS-PAGE was performed using a 7% NuPAGE Novex Tris-acetate gel and Tris-acetate running buffer (Invitrogen, Carlsbad, CA), and proteins were silver-stained.
| RESULTS AND DISCUSSION
Initial tests in a modified chromogenic assay using samples comprising parts of or the complete OS assay activation phase mixture confirmed two prerequisites for the subsequent investigations. The influence of the duration of the contact activation phase on N8-GP activity assessment was studied with APTT-SP and Pathromtin SL using three incubation times; the recommended time (see Table 1 ), plus a reduced and an extended duration. It turned out that N8-GP activity estimation in the OS clot assay depended on the duration with both reagents. The recommended incubation times resulted in a longer clotting time for N8-GP than for N8 when using APTT-SP (underestimating) and indistinguishable clotting times with *Individual rates are defined as the increase in FVIIIa cofactor activity (measured as generated FXa chromogenic activity) over 90 s (activity after 150 s exposure to thrombin subtracted by that after 60 s [depicted in Figure 3A] ).
Pathromtin SL (returns the expected recovery of N8-GP activity) (Figure 2A) . Underestimation of N8-GP activity with APTT-SP could be avoided by using a shorter contact activation phase of 90 seconds, (Table 1) .
Being central in the above hypothesis, the kinetics of activation by thrombin was assessed for N8-GP and N8. After different incubation times with thrombin, the resulting FVIIIa cofactor (tenase) activity was quantified as FXa formation. In the presence of APTT-SP, FVIIIa developed significantly slower from N8-GP than N8
( Figure 3A) . If buffer replaced APTT-SP, identical processing rates were observed for the two FVIII forms. The rates of N8-GP activation in the absence and presence of APTT-SP were similar, whereas the rate of N8 activation was apparently enhanced by APTT-SP, plausibly owing to local accumulation of favorably oriented N8 molecules on the silica. Ratios between the rates of N8-GP and N8 activation by thrombin are summarized in Table 2 . For the data to be useful, the activation of both FVIII forms needed to be detectable and linear over the time period, a requirement that necessitated the use of different thrombin concentrations for different reagents (see Table 2 ). The ratios obtained were generally below what would be expected based on the N8-GP activity recoveries obtained in the FXa and OS clot assays. This includes a ratio for Pathromtin SL significantly below one (0.30), albeit considerably higher than for the closely grouped underestimating APTT reagents (~0.1). The low ratios might be due to very different concentrations of thrombin generated in the FXa and OS clot assays compared with those used in the thrombin activation assay, as well as owing to other differences in experimental conditions. Nonetheless, a ratio clearly below 1 for Pathromtin SL would explain why N8-GP eventually becomes underestimated when the contact activation phase lasts sufficiently long ( Figure 2A ).
The decreased activation rate of N8-GP in the presence of APTT-SP was not evidently owing to PEG-mediated adsorption, since N8-GP and N8 appeared to stick to similar degrees to the surface of the silica particles ( Figure 3B ). However, the two FVIII forms may adsorb in, or distribute in a unique manner between, different preferred orientations or conformations on the silica, resulting in less accessibility of N8-GP for thrombin cleavage.
In summary, OS FVIII clotting assays are generally used to monitor hemophilia A treatment, making it very important that they estimate N8-GP clotting activity accurately. 12 Although a majority of APTT reagents return an acceptable recovery of N8-GP activity, the choice of reagent can matter. The duration of the contact activation phase also influences the recovery. Our data provide a potential simple remedy for N8-GP activity underestimation when using APTT-SP, namely shortening of the contact activation phase (to 90 seconds). This option to totally eliminate the underestimation of N8-GP activity may however be unique for APTT-SP. In a broad sense, our findings infer that whenever thrombin activates modified FVIII with slower kinetics than native FVIII, underestimation of EHL FVIII activity will occur when FXIa accumulates to above a certain threshold level. Above this reagent-specific level, subsequent FIXa formation occurs fast enough to reveal attenuated activation of EHL FVIII.
Finally, our compiled findings with N8-GP (herein) and N9-GP 11, 13 illustrate how a common type of modification ("activation peptide" glycoPEGylation) can elicit various mechanisms in the presence of the contact activator of an APTT reagent. These mechanisms influence APTT-based procoagulant activity estimations, whereas measurements of N8-GP and N9-GP activity triggered directly by FXIa are unaffected by the PEGylations.
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